Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Walgreens said it had entered into a settlement agreement with telemedicine provider Everly Health Solutions as part of which ...

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The domestic equity benchmarks closed near flat line on Tuesday, with investors cautiously awaiting key US economic data, including Core PCE and GDP figures, impacting Federal Reserve policy ...